David Douglass
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (3)
Year:
2025
Background In retrospective analyses, the Pediatric Oncology Group [POG) and the Federation National des Centres de Lutte Contre le Cancer (FNCLCC) histologic grade predict outcome in pediatric non‐rhabdomyosarcoma soft tissue sarcoma (NRSTS), but prospective data on grading, clinical features, and outcomes of low‐grade NRSTS are limited. Methods We analyzed patients less than 30 years of age enrolled on Children's Oncology Group (COG) study ARST0332 (NCT00346164) with POG grade 1 or 2 NRSTS. Low‐risk patients were treated with surgery alone. Intermediate‐/high‐risk patients received ifosfamide/doxorubicin and radiotherapy, with definitive resection either before or after 12 weeks of chemoradiotherapy. Results Estimated 5‐year event‐free and overall survival were 90% and 100% low risk ( n = 80), 55% and 78% intermediate risk ( n = 15), and 25% and 25% high risk ( n = 4). In low‐risk patients, only local recurrence was seen in 10%; none with margins greater than 1 mm recurred locally. Sixteen of 17 intermediate‐/high‐risk patients who completed neoadjuvant chemoradiotherapy underwent gross total tumor resection, 80% with negative margins. Intermediate‐/high‐risk group events included one local and seven metastatic recurrences. Had the FNCLCC grading system been used to direct treatment, 29% of low‐risk (surgery alone) patients would have received radiotherapy ± chemotherapy. Conclusions Most low‐risk patients with completely resected POG low‐grade NRSTS are successfully treated with surgery alone, and surgical margins greater than 1 mm may be sufficient to prevent local recurrence. Patients with intermediate‐ and high‐risk low‐grade NRSTS have outcomes similar to patients with high‐grade histology, and require more effective therapies. Use of the current FNCLCC grading system may result in overtreatment of low‐risk NRSTS curable with surgery alone.
Year:
2024
Year:
2023
Collaborators (8)
Sheri L. Spunt
Endowed Professor of Pediatric Cancer
Stanford University School of Medicine
Raya Saab
Stanford University
Alice Soragni
University of California
Ajay Gupta
Assistant Professor
Roswell Park Comprehensive Cancer Center
Jessica L. Davis
Indiana University School of Medicine
Alberto Pappo
Member
St. Jude Children's Research Hospital
Sapna Oberoi
Associate Professor
University of Manitoba
Susan M. Hiniker
Stanford University
Make your next move.
Prepare your application
Review drafts before you send them.